June 4, 2025 10:25 AM EDT

Vigil drug fails a Phase 2; Merus aims to raise $300M

ENDPOINTS

Plus, news about Bayer:

Vigil Neuroscience’s Phase 2 fail: The neurodegenerative disease biotech stopped a long-term extension trial of iluzanebart for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...